Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid entities : Gilead sciences, inc. save search
Coronavirus (COVID-19) Current Therapy Market Sees Antiviral Drugs Accounting For A Large Number Of Treatments
Published: 2022-03-15 (Crawled : 16:00) - prnewswire.com
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: 0.47%
H: 0.62%
C: -0.18%
covid-19 viral drug treatment drug covid therapy antiviral
NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment
Published: 2022-02-15 (Crawled : 14:00) - prnewswire.com
NRXP | $4.325 -11.74% -13.29% 270K
|
Manufacturing
|
| O: 1.66%
H: 9.15%
C: -0.65%
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: 0.01%
H: 0.65%
C: 0.35%
covid-19 zyesami aviptadil health als covid yes enroll
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Published: 2021-12-21 (Crawled : 11:00) - biospace.com/
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: 0.0%
H: 0.17%
C: -0.87%
covid-19 treatment europe risk oxygen covid disease
Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Published: 2021-12-07 (Crawled : 10:00) - globenewswire.com
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
europe covid covid-19
CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Published: 2021-12-06 (Crawled : 15:00) - globenewswire.com
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
approval covid chmp covid-19
Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia
Published: 2021-10-19 (Crawled : 14:00) - biospace.com/
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: 0.15%
H: 1.5%
C: 1.36%
covid ongoing
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
Published: 2021-09-22 (Crawled : 14:00) - biospace.com/
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: 0.47%
H: 0.15%
C: -0.96%
covid risk covid-19
Global $9.9 Billion Remdesivir Markets, 2021-2026 with 2020 as the Base Year - Focus on SARS-CoV-2 (COVID-19), MERS-CoV, Ebola, SARS-CoV
Published: 2021-08-12 (Crawled : 13:15) - prnewswire.com
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: 0.59%
H: 1.07%
C: 0.9%
covid sars-cov-2
NRx Pharmaceuticals Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife™ COVID Vaccine
Published: 2021-07-12 (Crawled : 15:15) - prnewswire.com
NRXP | $4.325 -11.74% -13.29% 270K
|
Manufacturing
|
| O: -2.09%
H: 31.85%
C: -14.37%
URGN | $14.57 -3.51% -3.64% 410K
|
Health Technology
|
| O: -0.74%
H: 0.74%
C: 0.2%
PYPD | $4.5 3.29% 810
|
Health Technology
|
| O: 4.35%
H: 0.0%
C: -4.5%
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: 0.93%
H: 1.22%
C: -0.23%
GLMD | $0.333 -11.46% -12.94% 97K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: -2.74%
covid israel partnership commercialization vaccine research
Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Published: 2021-06-25 (Crawled : 07:00) - globenewswire.com
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: -0.06%
H: 1.28%
C: 1.1%
covid treatment fda children merge authorized emergency use authorization
Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets
Published: 2021-06-21 (Crawled : 13:00) - biospace.com/
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: 0.57%
H: 0.86%
C: 0.54%
covid
Satcher Health Leadership Institute At Morehouse School Of Medicine, With Support From Google.org And Gilead Sciences, Launches Health Equity Tracker To Study Racial Health Inequities Related To Covid-19
Published: 2021-05-26 (Crawled : 12:00) - biospace.com/
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: -0.06%
H: 0.32%
C: 0.25%
covid health
Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia
Published: 2021-03-11 (Crawled : 09:00) - biospace.com/
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: -0.63%
H: 0.83%
C: -0.66%
covid trial
Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
Published: 2021-03-11 (Crawled : 07:00) - globenewswire.com
GILD | $67.32 -0.64% -0.64% 5M
|
Health Technology
|
| O: -0.63%
H: 0.83%
C: -0.66%
covid ev trial
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.